STAT+: U.K. readies a Netflix-style subscription payment model for badly needed antibiotics

"The math shows that major new antibiotics have a real social value that can be estimated and should be rewarded," said John Rex, chief medical officer at F2G.

Amid rising concern over antimicrobial resistance, the U.K. has taken a major step toward becoming the first country to launch an experimental payment model for antibiotics, a move designed to usher in a new era of drug development and reimbursement.

The government completed a long-awaited cost-effectiveness review of two new antibiotics as part of a pilot program that would pay for the medicines using a so-called subscription model. The idea is to pay companies upfront fees based on the estimated value of benefits to patients and the country’s National Health Service, rather than payments based on volumes used.

Continue to STAT+ to read the full story…